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ABSTRACT 
Background: The value of genetic thrombophilia testing in elderly patients with an 
unprovoked venous thromboembolism (VTE) is unclear. We assessed whether the 
factor V (FV) Leiden and the prothrombin G20210A mutation are associated with 
recurrent VTE in elderly patients in a prospective multicenter cohort study. 
Methods: We genotyped the factor V Leiden and the prothrombin G20210A mutation 
in 354 consecutive in- and outpatients aged ≥65 years with a first unprovoked venous 
thromboembolism from nine Swiss hospitals. Patients and managing physicians were 
blinded to testing results. The outcome was recurrent symptomatic venous 
thromboembolism during follow-up. We examined the association between the factor 
V Leiden and the prothrombin G20210A mutation and venous thromboembolism 
recurrence using competing risk regression, adjusting for age, sex, and periods of 
anticoagulation as a time-varying covariate. 
Results: Overall, 9.0% of patients had a factor V Leiden and 3.7% a prothrombin 
G20210A mutation. The At 36 months of follow-up, patients with a factor V Leiden 
and a prothrombin G20210A mutation had a cumulative incidence of recurrent 
venous thromboembolism of 12.9% (95% confidence interval [CI] 5.1-30.8%) and 
18.5% (95% CI 4.9-56.5%), respectively, compared to 16.7% (95% CI 12.5-22.1%) of 
patients without mutation (P=0.91 by the log-rank test). After adjustment, neither the 
factor V Leiden (sub-hazard ratio [SHR] 0.98; 95% CI 0.35-2.77) nor the prothrombin 
G20210A mutation (SRH 1.15; 95% CI 0.25-5.19) was associated with recurrent 
venous thromboembolism. 
Conclusion: In elderly patients with a first unprovoked VTE, thrombophilic mutations 
were not associated with an increased risk of recurrent VTE. Our results suggest that 
testing for genetic thrombophilia may not be beneficial in elderly patients with a first 
unprovoked venous thromboembolism 
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BACKGROUND 
Genetic thrombophilia, such as the factor V (FV) Leiden and the prothrombin 
G20210A mutation, are associated with an increased risk for a first venous 
thromboembolism (VTE) [1, 2]. However, while the association between these 
mutations and a first VTE is well accepted, it remains controversial whether such 
mutations also carry a higher risk of recurrent venous thromboembolism. A meta-
analysis of prospective studies demonstrated a slightly increased risk of recurrent 
venous thromboembolism in patients who had a heterozygous FV factor V Leiden 
(relative risk 1.4, 95% CI 1.1-1.8) or prothrombin G20210A mutation (relative risk 1.7, 
95% CI 1.3-2.3) [3]. 
Although the incidence of venous thromboembolism rises with age and venous 
thromboembolism carries a worse prognosis in older patients, including a potential 
17% increase in recurrent venous thromboembolism per decade [4, 5], prior studies 
that examined the risk of recurrent venous thromboembolism related to genetic 
thrombophilia either explicitly excluded elderly patients or enrolled mainly younger 
individuals (mean age 50-67 years) [3]. Thus, the relationship between genetic 
thrombophilia and the risk of recurrent venous thromboembolism in elderly patients 
with unprovoked venous thromboembolism remains unknown. To fill this gap of 
knowledge, we aimed to evaluate whether the factor V Leiden and prothrombin 
G20210A mutations are associated with recurrent venous thromboembolism in a 
prospective multicenter cohort study of elderly patients with a first unprovoked 
venous thromboembolism. 
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METHODS 
Study design, setting, and participants 
This study was conducted between September 2, 2009 and December 6, 2013 
as part of the Swiss Venous Thromboembolism Cohort (SWITCO65+), a prospective 
multicenter cohort study that assessed long-term medical outcomes in elderly 
patients with acute venous thromboembolism from five university and four high-
volume non-university hospitals in Switzerland [6]. Consecutive patients aged ≥65 
years with an acute, objectively confirmed, symptomatic venous thromboembolism 
were prospectively identified in the in- and outpatient services of all participating 
study sites. Symptomatic pulmonary embolism (PE) was defined as a positive spiral 
computed tomography or pulmonary angiography, a high probability ventilation-
perfusion scan, or proximal deep vein thrombosis (DVT) documented by compression 
ultrasonography or contrast venography in patients with acute chest pain, new or 
worsening dyspnea, hemoptysis, or syncope. Symptomatic deep vein thrombosis 
was defined as an acute onset of leg pain or swelling plus incomplete compressibility 
of a venous segment on ultrasonography or an intraluminal filling defect on contrast 
venography. The detailed study methods were previously published [6]. The study 
was approved by the Institutional Review Board at each participating center. 
For this study, we included only patients with a first unprovoked venous 
thromboembolism, defined as venous thromboembolism occurring in the absence of 
immobilization (fracture or cast of the lower extremity, bed rest >72 hours, or voyage 
in sitting position for >6 hours), major surgery, oral estrogen therapy, or active cancer 
(surgery, chemotherapy, radiotherapy, or palliative care) during the last three months. 
 
Baseline data collection and thrombophilia testing 
Trained study nurses prospectively collected baseline demographics (age and 
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sex), comorbid conditions (history of prior venous thromboembolism, major surgery, 
immobilization, and active cancer), estrogen therapy, and venous thromboembolism -
related treatments (low-molecular-weight heparin, unfractionated heparin, 
fondaparinux, vitamin K antagonists) from all enrolled patients using standardized 
data collection forms. 
DNA was extracted from frozen EDTA whole blood shortly after the index 
venous thromboembolism event and used for polymerase chain reaction assays of 
the factor V Leiden (QIAamp DNA Blood Mini QIAcube kit, Qiagen AG®, Switzerland) 
and prothrombin G20210A mutation (Roche Diagnostics AG®, Switzerland) in a core 
laboratory. Patients and managing physicians were blinded to the test results. 
 
Outcome 
The outcome was the recurrence of an objectively confirmed, symptomatic 
venous thromboembolism, defined as a fatal or new non-fatal pulmonary embolism or 
new proximal or distal deep vein thrombosis based on predefined imaging criteria or 
autopsy findings, as previously described [6]. Follow-up included semi-annual 
contacts, alternating between face-to-face evaluations (clinic visits or home visits in 
house-bound patients) and telephone calls as well as periodic reviews of the patient’s 
hospital chart. During each visit/contact, study nurses interviewed patients to obtain 
information about the date and type of clinical events (recurrent venous 
thromboembolism, death). If a clinical event had occurred, this information was 
complemented by reviewing medical charts and interviewing patients’ primary care 
physicians and family members. We also collected international normalized ratio 
(INR) values throughout follow-up. 
An independent committee of three clinical experts blinded to the testing 
results adjudicated the outcomes and classified the cause of all deaths as definitely 
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due to pulmonary embolism, possibly due to pulmonary embolism (e.g., sudden 
death without obvious cause), or due to another cause. Fatal PE was defined as 
death due to definite or possible PE. Death was judged to be pulmonary embolism-
related if confirmed by autopsy, or if death followed a clinically severe pulmonary 
embolism, either initially or after an objectively confirmed recurrent event. Pulmonary 
embolism unrelated deaths were the result of an obvious cause other than pulmonary 
embolism, such as an initially unknown cancer, bleeding, acute coronary syndrome, 
left ventricular failure, stroke, or other causes (e.g., sepsis, suicide, or accident). Final 
classification was made on the basis of the full consensus of this committee. 
 
Statistical analyses 
We calculated the incidence rates of a first recurrent venous thromboembolism 
in patients with a factor V Leiden mutation, a prothrombin G20210A mutation, and 
those without mutations. We compared cumulative incidences of recurrent venous 
thromboembolism in patients with thrombophilic mutations to those without mutations 
using Kaplan-Meier curves and the log-rank test. In patients receiving vitamin K 
antagonists, we also compared the quality of anticoagulation, expressed as the 
percentage of time within the therapeutic INR range (2.0-3.0), between patients with 
and without mutations [7]. We examined associations between thrombophilic 
mutations and the time to a first venous thromboembolism recurrence using 
competing risk regression according to Fine and Grey, accounting for non-pulmonary 
embolism-related death as a competing event [8]. The strength of the association is 
reflected by the sub-hazard ratio (SHR), which is the ratio of hazards associated with 
the cumulative incidence function in the presence of a competing risk. We adjusted 
the model for age, sex, and periods of anticoagulation as a time-varying covariate. In 
our primary analysis, we included the entire follow-up period, regardless of whether 
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patients were under anticoagulants or not. In a sensitivity analysis, we considered 
only the observation period after completion of the initial anticoagulant treatment. All 
analyses were done using Stata 14 (Stata Corporation, College Station, Texas). 
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RESULTS 
Study sample 
Overall, 1003 patients were enrolled in our cohort. We excluded 215 patients 
with provoked venous thromboembolism, 204 with a history of prior venous 
thromboembolism, 181 with cancer-related venous thromboembolism, and 8 denying 
use of their data, leaving 395 patients with a first unprovoked venous 
thromboembolism. After the exclusion of another 41 patients (40 without genotyping 
and 1 with early consent withdrawal), our final study sample comprised 354 elderly 
patients with a first acute unprovoked symptomatic venous thromboembolism. 
Overall, there was no statistically significant difference in age and sex between 
analyzed and excluded patients with a first unprovoked venous thromboembolism 
(data not shown). 
Analyzed patients had a median age of 75 years, 46% were women, 257 
(73%) had pulmonary embolism ± deep vein thrombosis, 79 (22%) proximal ±distal 
DVT, and 18 (5%) isolated distal DVT as the initial VTE event. Overall, 32 patients 
(9.0%) had a factor V Leiden (31 heterozygous, 1 homozygous), 13 (3.7%) a 
prothrombin G20210A (all heterozygous), and 1 (0.3%) both mutations (both 
heterozygous). Patients with a prothrombin G20210A mutation were older than 
patients with a factor V Leiden or no mutation, but otherwise, groups did not differ in 
terms of patient baseline characteristics (Table 1). 
 
Comparison of recurrent VTE 
The median follow-up period was 30 months (interquartile range 24-41 
months). Overall, 29 (91%) of patients with a factor V Leiden mutation, 12 (100%) of 
patients with a prothrombin G20210A mutation, and 273 (88%) of patients without 
mutations received anticoagulants for >3 months (P=0.41). The median duration of 
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initial anticoagulation was 7.1 months in patients with a factor V Leiden, 20.2 months 
in patients with a prothrombin G20210A, and 8.2 months in patients without 
mutations, but the differences did not reach statistical significance (P=0.07). In the 
342 of 354 patients who received vitamin K antagonists, the percentage of time 
within the therapeutic INR range (2.0-3.0) did not differ in patients with a factor V 
Leiden (59%), prothrombin G20210A (67%), and no mutation (67%) (P=0.23). 
Overall, 54 of 354 patients (15.3%) had recurrent venous thromboembolism 
during follow-up, resulting in an overall incidence of recurrent VTE of 7.0 (95% 
confidence interval [CI] 5.3-9.1) events per 100 patient-years. Fifty-six patients (16%) 
died during follow-up. Of these, 14 (25%) died from pulmonary embolism. No patient 
with a thrombophilic factor died from pulmonary embolism. At 36 months, the 
cumulative incidence of VTE was 12.9% (95% CI 5.1-30.8%) in patients with a factor 
V Leiden, 18.5% (95% CI 4.9-56.5%) in patients with a prothrombin G20210A, and 
16.7% (95% CI 12.5-22.1%) in patients without a mutation (P=0.91; by the logrank 
test, see Figure). 
 
Association between thrombophilic mutations and recurrent VTE 
After adjustment for age, sex, and periods of anticoagulation as a time-varying 
covariate, thrombophilic mutations were not associated with recurrent venous 
thromboembolism, with a SHR of 0.98 (95% CI 0.35-2.77) for the factor V Leiden and 
1.15 (95% CI 0.25-5.19) for the prothrombin G20210A mutation (Table 2). When we 
considered only observation periods after the completion of the initial anticoagulation, 
the results were similar (Table 2). 
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DISCUSSION 
In this prospective multicenter cohort of elderly patients with a first unprovoked 
venous thromboembolism, the factor V Leiden and the prothrombin G20210A 
mutation were not associated with venous thromboembolism recurrence. Prior 
prospective studies demonstrated that genetic thrombophilia is only a very modest 
predictor of recurrence (relative risk 1.4 to 1.8) in younger patients with unprovoked 
venous thromboembolism [3]. Our results confirm that the prognostic impact of 
genetic thrombophilia is even less relevant in the elderly, possibly, because clinical 
factors, such as comorbid conditions, may be stronger drivers of venous 
thromboembolism recurrence than genetic thrombophilic factors [5]. 
Given the absence of randomized trials, high-quality evidence on the 
usefulness of genetic thrombophilia testing following unprovoked venous 
thromboembolism is lacking. In a case-control study, testing for factor V Leiden and 
prothrombin G20210A mutations in patients with a first venous thromboembolism 
was not associated with a reduced incidence of recurrent venous thromboembolism 
[9]. Similarly, testing for genetic thrombophilia did not influence medical management 
in 77% of tested patients [10]. Evidence suggests that even combined heterozygous 
or single homozygous factor V Leiden or prothrombin G20210A mutations do not 
appear to carry a relevant venous thromboembolism recurrence risk [11] and that the 
venous thromboembolism risk becomes substantial only among the very rare 
individuals with compound homozygous mutations of these polymorphisms [12]. 
Given the high costs of testing (approximately $300) [13] and its presumed 
lack of benefit, genetic thrombophilia testing is not useful in elderly patients with a 
first unprovoked venous thromboembolism [14, 15]. Although current guidelines do 
not support genetic thrombophilia testing for predicting recurrent venous 
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thromboembolism [14, 16, 17], testing continues to be done in one out of five patients 
aged more than 50 years with a first unprovoked venous thromboembolism [18]. 
Our study, to our knowledge the only existing prospective cohort study 
examining the usefulness of genetic thrombophilia testing in the elderly with 
unprovoked venous thromboembolism, has several strengths. First, we enrolled 
patients from university and non-university hospitals, increasing the generalizability of 
our results. Second, patients and managing physicians were blinded to testing 
results, which makes a performance bias unlikely. While we cannot entirely rule out 
the possibility that managing physicians ordered thrombophilia testing outside the 
study protocol, the comparable anticoagulation durations (with the exception of a 
somewhat longer anticoagulation duration in patients with a prothrombin G20210A 
mutation) and quality in patients with and without thrombophilia do not support this 
possibility. Finally, outcomes were adjudicated by an independent committee blinded 
to the testing results, decreasing the risk of a detection bias (i.e., higher venous 
thromboembolism observation rates in patients with thrombophilia). 
Our study has also potential limitations. First, our analysis is based on a 
subsample of a prospective cohort study and we did not perform a formal sample 
size calculation to answer our research question. While our study may not have 
sufficient power to detect small associations between thrombophilic mutations and 
recurrent venous thromboembolism, the point estimates around 1 indicate that even 
a much larger sample would not have allowed for the detection of a significant 
association. Besides, our sample size of 354 elderly patients compares well with the 
sample sizes of similar prospective studies conducted in younger patients with a first 
unprovoked venous thromboembolism [19, 20]. Second, because the observation 
period in our primary analysis included also the initial anticoagulation period, the risk 
of venous thromboembolism recurrence may have been lower than expected. 
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However, when we considered only observation periods after the completion of the 
initial anticoagulation in a sensitivity analysis, our results remained similar, confirming 
the robustness of our findings. Finally, we could not examine whether patients who 
had completed their initial course of anticoagulation subsequently received aspirin, 
which could potentially lead to a performance bias. 
In conclusion, our results demonstrate that in elderly patients with a first 
unprovoked venous thromboembolism, genetic thrombophilia is not associated with 
an increased risk of venous thromboembolism recurrence. Although additional study 
is needed, our data suggest that testing for genetic thrombophilia may not be 
beneficial in elderly patients with a first unprovoked VTE.  
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Figure Legend 
Cumulative incidence of recurrent venous thromboembolism 
The cumulative 36-month incidence of venous thromboembolism was 12.9% (95% 
confidence interval [CI] 5.1-30.8%) in patients with a factor V Leiden, 18.5% (95% CI 
4.9-56.5%) in patients with a prothrombin G20210A, and 16.7% (95% CI 12.5-22.1%) 
in patients without mutation (P=0.91 by the logrank test). 
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Table 1. Patient baseline characteristics 
Characteristic Factor V 
Leiden 
mutation* 
(N=32) 
Prothrombin 
20210A mutation 
(N=12) 
No 
mutation 
(N=310) 
P-
value 
 Median (IQR) or n (%)  
Age, years 72 (68-77) 78 (72-81) 76 (70-83) 0.04 
Age ≥80 years 4 (13) 6 (50) 106 (34) 0.02 
Female sex 12 (38) 4 (33) 148 (48) 0.36 
Clinical manifestation of venous 
thromboembolism 
    
Pulmonary embolism ±deep 
vein thrombosis 
20 (63) 8 (67) 229 (74) 0.51 
Proximal ±distal deep vein 
thrombosis 
10 (31) 4 (33) 65 (21)  
Isolated distal deep vein 
thrombosis 
2 (6) 0 (0) 16 (5)  
Initial parenteral anticoagulation†    0.57 
Low-molecular-weight heparin 15 (47) 5 (42) 154 (50)  
Unfractionated heparin 6 (19) 4 (33) 89 (29)  
Fondaparinux 10 (31) 3 (25) 55 (18)  
None 1 (3) 0 (0) 12 (4)  
Vitamin K antagonist treatment 31 (97) 12 (100) 299 (96) 0.80 
 
Abbreviations: IQR= interquartile range; VTE= venous thromboembolism; PE= pulmonary embolism; 
DVT= deep vein thrombosis; AC= anticoagulation. 
*1 patient had both a heterozygous FV Leiden and a prothrombin G20210A mutation. 
†Percentages may not add up to 100% due to rounding.  
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Table 2. Association between thrombophilic mutations and recurrent venous 
thromboembolism 
Thrombophilic mutation Number of 
events/patients 
Unadjusted SHR 
(95% CI) 
Adjusted* SHR 
(95% CI) 
Full observation period 
 
  
No mutation 48/310 1 (reference) 1 (reference) 
Factor V Leiden† 4/32 0.80 (0.29-2.24) 0.98 (0.35-2.77) 
Prothrombin G20210A 2/12 1.21 (0.27-5.47) 1.15 (0.25-5.19) 
After initial anticoagulation only    
No mutation 41/190 1 (reference) 1 (reference) 
Factor V Leiden† 3/24 0.51 (0.15-1.71) 0.62 (0.19-2.10) 
Prothrombin G20210A 0/3 ‡ ‡ 
 
Abbreviations: SHR= sub-hazard ratio; CI= confidence interval. 
*Adjusted for age, sex, and periods of anticoagulation as a time-varying covariate. 
†Including 1 patient with both a heterozygous FV Leiden and prothrombin G20210A mutation. 
‡Not estimable because no patient with a prothrombin G20210A mutation had recurrent VTE after 
stopping initial anticoagulation. 
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Figure 
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Table 1. Patient baseline characteristics 
Characteristic Factor V 
Leiden 
mutation* 
(N=32) 
Prothrombin 
20210A 
mutation 
(N=12) 
No 
mutation 
(N=310) 
P-value 
 Median (IQR) or n (%)  
Age, years 72 (68-77) 78 (72-81) 76 (70-83) 0.04 
Age ≥80 years 4 (13) 6 (50) 106 (34) 0.02 
Female sex 12 (38) 4 (33) 148 (48) 0.36 
Clinical manifestation of venous 
thromboembolism 
    
Pulmonary embolism ±deep 
vein thrombosis 
20 (63) 8 (67) 229 (74) 0.51 
Proximal ±distal deep vein 
thrombosis 
10 (31) 4 (33) 65 (21)  
Isolated distal deep vein 
thrombosis 
2 (6) 0 (0) 16 (5)  
Initial parenteral anticoagulation†    0.57 
Low-molecular-weight heparin 15 (47) 5 (42) 154 (50)  
Unfractionated heparin 6 (19) 4 (33) 89 (29)  
Fondaparinux 10 (31) 3 (25) 55 (18)  
None 1 (3) 0 (0) 12 (4)  
Vitamin K antagonist treatment 31 (97) 12 (100) 299 (96) 0.80 
 
Abbreviations: IQR= interquartile range 
*1 patient had both a heterozygous factor V Leiden and a prothrombin G20210A mutation. 
†Percentages may not add up to 100% due to rounding.  
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Table 2. Association between thrombophilic mutations and recurrent venous 
thromboembolism 
Thrombophilic mutation Number of 
events/patients 
Unadjusted SHR 
(95% CI) 
Adjusted* SHR 
(95% CI) 
Full observation period    
No mutation 48/310 1 (reference) 1 (reference) 
Factor V Leiden† 4/32 0.80 (0.29-2.24) 0.98 (0.35-2.77) 
Prothrombin G20210A 2/12 1.21 (0.27-5.47) 1.15 (0.25-5.19) 
After initial anticoagulation only    
No mutation 41/190 1 (reference) 1 (reference) 
Factor V Leiden† 3/24 0.51 (0.15-1.71) 0.62 (0.19-2.10) 
Prothrombin G20210A 0/3 ‡ ‡ 
 
Abbreviations: SHR= sub-hazard ratio; CI= confidence interval. 
*Adjusted for age, sex, and periods of anticoagulation as a time-varying covariate. 
†Including 1 patient with both a heterozygous FACTOR V Leiden and prothrombin G20210A mutation. 
‡Not estimable because no patient with a prothrombin G20210A mutation had recurrent venous 
thromboembolism after stopping initial anticoagulation. 
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Clinical significance 
• In elderly patients with a first unprovoked venous thromboembolism, the 
prevalence of Factor V Leiden and prothrombin G20210A mutations was 9.0% 
and 3.7%, respectively 
• These mutations were not associated with long-term venous 
thromboembolism recurrence 
• Costly testing for genetic thrombophilia may not be beneficial in elderly 
patients with a first unprovoked venous thromboembolism 
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Clinical significance 
• The value of genetic thrombophilia testing in elderly with a first unprovoked 
venous thromboembolism  is unclear 
• In our prospective cohort of elderly patients with a first unprovoked venous 
thromboembolism, the prevalence of Factor V Leiden and prothrombin 
G20210A mutations was 9.0% and 3.7%, respectively 
• We found no association between These mutations were not associated with 
long-term venous thromboembolism recurrence 
• and long-term venous thromboembolism recurrence 
• Costly testing for genetic thrombophilia is unlikely to carry any benefit in 
elderly patients with a first unprovoked VTE may not be beneficial in elderly 
patients with a first unprovoked venous thromboembolism 
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FIGURE 
Cumulative incidence of recurrent venous thromboembolism 
The cumulative 36-month incidence of venous thromboembolism was 12.9% (95% 
confidence interval [CI] 5.1-30.8%) in patients with a factor V Leiden, 18.5% (95% CI 
4.9-56.5%) in patients with a prothrombin G20210A, and 16.7% (95% CI 12.5-22.1%) in 
patients without mutation (P=0.91 by the logrank test). 
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